Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 21, 2006British Journal of Haematology

Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS‐13

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMarie ScullyUniversity College HospitalHCHannah CohenUniversity College London Hospitals NHS Foundation TrustJCJamie CavenaghSt Bartholomew's Hospital

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Scully et al. (2006) studied this question.

synapsesocial.com/papers/6a9f5fa64e5f4deab168ffe0https://doi.org/10.1111/j.1365-2141.2006.06448.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.1998 · 2,771 citations
  2. 2Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura1991 · 1,940 citations
  3. 3Late Relapses in Patients Successfully Treated for Thrombotic Thrombocytopenic Purpura1995 · 176 citations
  4. 4Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature2004 · 120 citations
  5. 5Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP)2004 · 79 citations